XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults

Key Inclusion Criteria:

• Healthy male or female participants, aged 18 to 55 years (inclusive at the time ofinformed consenting);

• Participants must be in good general health, with no significant medical history,and have no clinically significant abnormalities on physical examination atScreening and/or before administration of study drug;

• Stable body weight for at least 3 months prior to Screening (i.e., <5% change) byself-declaration;

• Participants must have a Body Mass Index (BMI) ≥22.0 kg/m2 and <32.0 kg/m2 and weigh ≥55 kg at Screening (Cohorts 1A/1B to 3), or participants must have a BMI ≥30.0kg/m2 and <40.0 kg/m2 and weigh ≥75 kg at Screening (Cohort 4, 5 and 6 only);

Key Exclusion Criteria:

• Prior or ongoing medical conditions, medical history, physical findings, orlaboratory abnormality that, in the Investigator's (or delegate's) opinion, mayrequire treatment or render the participant unlikely to fully complete the study, orany condition that presents undue risk from the investigational product (IP) orprocedures or interfere with study assessments;

• Confirmed diagnosis of diabetes mellitus type 1, type 2, or of any other forms atany time, and/or occurrence of documented or suspected hypoglycaemic episodes within 12 months prior to Screening;

• Personal or family history of medullary thyroid carcinoma or multiple endocrineneoplasia type 2;